Andrew T Day1,2, Kristina R Dahlstrom3, Rebecca Lee1, Maher Karam-Hage4, Erich M Sturgis2,5. 1. Department of Otolaryngology-Head and Neck Surgery, UT Southwestern Medical Center, Dallas, Texas, USA. 2. Population Science & Cancer Control, UT Southwestern Simmons Comprehensive Cancer Center, Dallas, Texas, USA. 3. Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 4. Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5. Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND: Approximately one quarter of head and neck cancer (HNC) patients smoke cigarettes at the time of diagnosis. Despite HNC guideline recommendations to treat tobacco dependence, the effectiveness of treatment in this population is poorly described. METHODS: This retrospective cohort review evaluated 117 current smokers with p16-negative mucosal head and neck squamous cell carcinoma prospectively enrolled in a tobacco treatment program. Seven-day point prevalence tobacco abstinence rates at 9 months and survival outcomes were compared among abstinent and nonabstinent groups. RESULTS: Median follow-up among survivors was 62.4 months. Forty percent of patients were abstinent at 9 months according to intention-to-treat analysis. After adjustment for age, comorbidity and site, abstinent stage I to II patients had a decreased risk of death compared to smoking stage I to II patients (HR 0.15, 95% CI 0.03-0.82). CONCLUSIONS: High cohort abstinence rates and favorable survival among abstinent patients with early-stage HNC confirm the importance of tobacco dependence treatment in this population.
BACKGROUND: Approximately one quarter of head and neck cancer (HNC) patients smoke cigarettes at the time of diagnosis. Despite HNC guideline recommendations to treat tobacco dependence, the effectiveness of treatment in this population is poorly described. METHODS: This retrospective cohort review evaluated 117 current smokers with p16-negative mucosal head and neck squamous cell carcinoma prospectively enrolled in a tobacco treatment program. Seven-day point prevalence tobacco abstinence rates at 9 months and survival outcomes were compared among abstinent and nonabstinent groups. RESULTS: Median follow-up among survivors was 62.4 months. Forty percent of patients were abstinent at 9 months according to intention-to-treat analysis. After adjustment for age, comorbidity and site, abstinent stage I to II patients had a decreased risk of death compared to smoking stage I to II patients (HR 0.15, 95% CI 0.03-0.82). CONCLUSIONS: High cohort abstinence rates and favorable survival among abstinent patients with early-stage HNC confirm the importance of tobacco dependence treatment in this population.
Authors: Samuel J Wang; Amanda R Wissel; Celine B Ord; Jayashree Kalpathy-Cramer; C David Fuller; John M Holland; Neil D Gross Journal: Otolaryngol Head Neck Surg Date: 2011-07 Impact factor: 3.497
Authors: Sonia A Duffy; Angela L Scheumann; Karen E Fowler; Cynthia Darling-Fisher; Jeffrey E Terrell Journal: Oncol Nurs Forum Date: 2010-05 Impact factor: 2.172
Authors: Mark E Zafereo; Li Xu; Kristina R Dahlstrom; Carlo A Viamonte; Adel K El-Naggar; Qingyi Wei; Guojun Li; Erich M Sturgis Journal: Oral Oncol Date: 2016-03-21 Impact factor: 5.337
Authors: Robert A Schnoll; Randi L Rothman; Caryn Lerman; Suzanne M Miller; Holly Newman; Benjamin Movsas; Eric Sherman; John A Ridge; Michael Unger; Corey Langer; Melvyn Goldberg; Walter Scott; Jonathan Cheng Journal: Head Neck Date: 2004-03 Impact factor: 3.147
Authors: Laura J Viens; S Jane Henley; Meg Watson; Lauri E Markowitz; Cheryll C Thomas; Trevor D Thompson; Hilda Razzaghi; Mona Saraiya Journal: MMWR Morb Mortal Wkly Rep Date: 2016-07-08 Impact factor: 17.586
Authors: Xavier Castellsagué; Laia Alemany; Miquel Quer; Gordana Halec; Beatriz Quirós; Sara Tous; Omar Clavero; Llúcia Alòs; Thorsten Biegner; Tomasz Szafarowski; Maria Alejo; Dana Holzinger; Enrique Cadena; Edith Claros; Gillian Hall; Jan Laco; Mario Poljak; Maria Benevolo; Elena Kasamatsu; Hisham Mehanna; Cathy Ndiaye; Núria Guimerà; Belen Lloveras; Xavier León; Juan C Ruiz-Cabezas; Isabel Alvarado-Cabrero; Chang-Suk Kang; Jin-Kyoung Oh; Marcial Garcia-Rojo; Ermina Iljazovic; Oluseyi F Ajayi; Flora Duarte; Ashrafun Nessa; Leopoldo Tinoco; Marco A Duran-Padilla; Edyta C Pirog; Halina Viarheichyk; Hesler Morales; Valérie Costes; Ana Félix; Maria Julieta V Germar; Marisa Mena; Arzu Ruacan; Asha Jain; Ravi Mehrotra; Marc T Goodman; Luis Estuardo Lombardi; Annabelle Ferrera; Sani Malami; Estela I Albanesi; Pablo Dabed; Carla Molina; Rubén López-Revilla; Václav Mandys; Manuel E González; Julio Velasco; Ignacio G Bravo; Wim Quint; Michael Pawlita; Nubia Muñoz; Silvia de Sanjosé; F Xavier Bosch Journal: J Natl Cancer Inst Date: 2016-01-28 Impact factor: 13.506
Authors: Paul M Cinciripini; Maher Karam-Hage; George Kypriotakis; Jason D Robinson; Vance Rabius; Diane Beneventi; Jennifer A Minnix; Janice A Blalock Journal: JAMA Netw Open Date: 2019-09-04
Authors: Saverio Caini; Marco Del Riccio; Virginia Vettori; Oriana D'Ecclesiis; Pierluigi Bonomo; Luca Giovanni Locatello; Viola Salvestrini; Oreste Gallo; Marta Tagliabue; Sara Raimondi; Calogero Saieva; Flavia Cozzolino; Benedetta Bendinelli; Sara Gandini Journal: Br J Cancer Date: 2022-08-23 Impact factor: 9.075